Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Changes Brewing At Bayer, But Pharma Strategy Remains On Point

Executive Summary

Bayer AG is pursuing an acquisition of seed manufacturer Monsanto Co. that would establish agriculture as the largest business unit within the diversified life sciences company, usurping pharmaceuticals as the top revenue generator. Bayer Head of Innovation Kemal Malik said the company’s commitment to pharmaceuticals remains unwavering despite the M&A play.


Related Content

Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline
European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate
Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease
Dekkers: New Bayer Is Stable And Fit To Innovate for All Species
Bayer Looks For New Partner As It Strives To Be A Player In Oncology Market


Related Companies